The newly integrated behavioral-miniscope platform is being launched through a co-marketing collaboration with Noldus Information Technology

MOUNTAIN VIEW, Calif. — Inscopix, Inc., a neuroscience company helping decode the brain for tomorrow’s treatments, announced the official release of Inscopix’s new multimodal behavioral technology called the nVision System, at Neuroscience 2022 being held in San Diego, California, November 12-16. The new innovation enables single-step synchronization between in vivo neural circuit imaging data from the company’s miniscope-based platforms and animal behavior video recordings, making experimental data collection and analysis easier than ever before for behavioral neuroscientists.

First announced in June 2022 and introduced in early November 2022 as a key product highlight at Neuroscience 2022, the nVision System is capable of the simultaneous capture of high-quality behavior and calcium imaging movies in a single session. The product has been designed to seamlessly integrate with researchers’ local behavioral setups, such as the open field test, elevated plus maze and social interaction tests. Neuroscience researchers can now use it to correlate brain and behavioral activities with unprecedented precision, a first-of-its-kind integrated technology to glean unique insights into brain health and disease. The company has received early positive feedback from select users. “The nVision system is an amazing addition to our miniscope nVue^TM system. Not only is it very user friendly and easy to set up and use, but the high-quality camera is super versatile and can be used in multiple different behavior setups and recording angles,” said Dr. Erin Carroll, a postdoctoral scientist working on an intruder paradigm at Dr. Moriel Zelikowsky’s Lab at the University of Utah. “It worked great for miniscope focused behavior assays and would even be beneficial to general behavior assays not using miniscopes.”

A co-marketing collaboration with Noldus Information Technology, which started in June 2022, encourages nVision customers to add Noldus’ pioneering EthoVision XT video tracking software to the nVision workflow. By plugging in the behavioral video into Noldus’ user-friendly interface, the software is capable of tracking and analyzing the behavior, movement, and activity of the animal being studied.

“As the first and only platform enabling both high-resolution acquisition of behavioral videos and precise synchronization with calcium imaging data, the nVision Platform saves valuable time and effort for our users while avoiding any data loss,” said Kunal Ghosh, Ph.D., CEO of Inscopix. “We’re very excited to release nVision to our community so they can focus their attention on the results and their interpretation, rather than the execution of the experiments.”

Inscopix at Neuroscience 2022

The IDEAS Platform, along with other innovations around the company’s miniature microscope-based brain mapping platforms, will be featured at Neuroscience 2022 being held in San Diego, California November 12-16. The Inscopix showcase at the meeting will highlight key product and applications updates, including:

• The flagship nVue^TM System for dual-color imaging
• Neurotransmitter and blood flow imaging applications
• The new nVision^TM Platform enabling one step synchronization between calcium imaging and free behavioral movies
• Core imaging and optogenetics capabilities in the nVista^TM System and nVoke^TM System, respectively.

The Inscopix booth will have scheduled demonstrations of the IDEAS Platform, sign-ups for which are currently open here. The nVision Platform, first announced in June 2022, will be on display at the booth for the first time.

The company is also offering the opportunity to book a 1:1 consultation here with the company’s expert scientists to see any and all of the products and applications in person while at the meeting. Inscopix will provide details of abstracts throughout the meeting via Twitter at @inscopix.

Presentations by Inscopix include:

• Tools for acquisition and analysis of simultaneous neural activity and vascular dynamics in freely behaving animals
  D. Ollerenshaw et al., Ph.D.
  Session 577 – Optical Methodology: Application
  Nov. 15, 2022 1:00 PM – 2:00 PM (PDT)

• Prefrontal cortex neuronal hyperactivity in a mouse model of Alzheimer’s beta-amyloidosis
  S. Huang et al., Ph.D.
  Session 120 – Alzheimer’s Disease: Biomarkers II
  Nov. 13, 2022 9:00 AM – 10:00 AM (PDT)

Meeting attendees can visit Inscopix at booth #1028, or email [email protected] to schedule a conversation with a member of the company.

About Inscopix, Inc.

Inscopix is a brain imaging platform company focused on decoding the mind to better understand and address all neurological disorders. We are solving perhaps the greatest unmet need in humanity – understanding how the brain works – and leveraging that knowledge to develop effective neurological treatments. With almost 200 peer-reviewed publications validating our innovative brain circuitry imaging technology, Inscopix is empowering the neuroscience research community to advance science while bringing a new generation of transformational therapeutics to patients with difficult-to-treat brain disorders. Learn more at inscopix.com and follow us @inscopix.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221110005382/en/

Contacts

Inscopix Contact:
Martin Verhoef
[email protected]

Media Contact:
Tim Ingersoll
[email protected]